Türk Medline
Dokran

FIFTEEN-YEAR TREATMENT OF METASTATIC THYROID MEDULLARY CARCINOMA: A CASE REPORT

OZEN OZ GUL, SONER CANDER, PİNAR SİSMAN, ERDİNC ERTURK, CANAN ERSOY

The European Research Journal - 2015;1(3):160-164

Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa, Turkey

 

Although very rare, medullary thyroid carcinoma (MTC) is the most aggressive in differentiated thyroid malignancies. We report a 48-year-old male patient with the diagnosis of MTC, who was monitored for fifteen years and showed no serious adverse events due to long-term chemotherapy. Total thyroidectomy, neck dissection, retrosternal nodule excision and pericardiectomy were performed, and radiotherapy was applied to the neck area. Due to progressive metastatic disease cyclophosphamide, dacarbazine, and vincristine were administrated. He tolerated chemotherapy well, and no severe systemic side effects were detected. He died due to multi-organ failure after fifteen years of diagnosis. The only curative treatment is surgery in MTC, however; radiotherapy, chemotherapy, and embolization may be used for patients for whom surgery cannot be performed. Although success rates of systemic chemotherapy are low, it is a treatment option in the progressive metastatic disease.